BCR-ABL-IN-9

• UNSPSC Description:

  BCR-ABL-IN-9 (Compound B1) is a BCR-ABL inhibitor that achieves sustained BCR-ABL suppression by forming stable covalent bonds with the ABL kinase. BCR-ABL-IN-9 is also effective in inhibiting the activity of the ABL kinase (IC50 = 1.2 nM). BCR-ABL-IN-9 possesses anticancer activity[1].

• Target Antigen:

  Bcr-Abl

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bcr-abl-in-9.html

• Smiles:

  OC1=CC=C(OC)C(C2=CNC3=NC=C(C4=CC(C(N(C)C)=O)=CN=C4)C=C23)=C1

• Molecular Weight:

  388.42

• References & Citations:

  [1]Sun J, et al. Rationally designed BCR-ABL kinase inhibitors for improved leukemia treatment via covalent and pro-/dual-drug targeting strategies[J]. Journal of Advanced Research, 2024.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported